Skip to content

US · HROW · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Harrow Health, Inc. (HROW) intrinsic value and stock valuation

$30.41as of 2026-11-21 · Mkt cap 1.47B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Harrow Health, Inc. DCF and intrinsic value

InvestorsCraft values HROW with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from HROW’s statements →

Harrow Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Nashville, TN 37215 harrow.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$272.3M+41% 5y CAGRd
20112025
Net income
-$-5.14M
20112025
Free cash flow
$42.8M
20112025
Total equity
$52.1M+14.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$272.3M$199.6M$130.2M$88.6M$72.5M
Operating income$38.6M$8.82M$430K$1.92M$1.61M
Net income-$-5.14M-$-17.48M-$-24.41M-$-14.09M-$-18.01M
EPSd-$-139.83K-$-490.32K-$-748.31K-$-513.11K-$-673.02K
Operating cash flow$43.9M-$-22.2M$3.84M$1.71M$5.08M
Capital expenditure-$-1.1M-$-38.67M-$-152.55M-$-7.77M-$-28.51M
Free cash flow$42.8M-$-60.88M-$-148.71M-$-6.07M-$-23.43M
Total assets$399.5M$389M$311.8M$157.4M$98.3M
Total debt$252M$228.8M$190.5M$112.2M$78M
Net debt$179.1M$181.6M$116.4M$16M$35.8M
Total equity$52.1M$69.3M$70M$27.2M$10.9M
Cash and short-term investments$72.9M$47.3M$82.8M$101.9M$50.7M
Income statement
20252024202320222021
Revenue$272.3M$199.6M$130.2M$88.6M$72.5M
Cost of revenue$67.9M$49.2M$39.6M$25.4M$18.2M
Gross profit$204.4M$150.4M$90.6M$63.2M$54.3M
Research and development expenses$12.9M$12.2M$6.65M$3.05M$11.1M
Selling, general and administrative expenses$152.9M$0.00$0.00$0.00$39.8M
Other expenses$0.00$129.3M$83.5M$58.2M$1.75M
Operating expenses$165.8M$141.6M$90.1M$61.3M$52.7M
Cost and expenses$233.7M$190.8M$129.8M$86.7M$70.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$24.2M$22.8M$21.3M$7.24M$5.44M
Depreciation and amortization$18.9M$13.1M$11.1M$2.83M$1.74M
Ebitda$41.4M$22.1M$12M-$-3.94M$5.1M
Operating income$38.6M$8.82M$430K$1.92M$1.61M
Total other income/expenses, net-$-40.33M-$-26.14M-$-24.14M-$-15.93M-$-19.49M
Income before tax-$-1.72M-$-17.32M-$-23.71M-$-14.01M-$-17.87M
Income tax expense$3.42M$160K$700K$70K$130K
Net income-$-5.14M-$-17.48M-$-24.41M-$-14.09M-$-18.01M
Weighted average shares outstanding$36.8M$35.7M$32.6M$27.5M$26.8M
Weighted average diluted shares outstanding$36.8M$35.7M$32.6M$27.5M$26.8M
Balance sheet
20252024202320222021
Cash and short-term investments$72.9M$47.3M$82.8M$101.9M$50.7M
Net receivables$110.9M$116.6M$36.5M$6.39M$4.52M
Inventory$13.5M$10.7M$10.9M$6.54M$4.22M
Total current assets$211.8M$189.7M$139.1M$118.3M$60.7M
Property, plant and equipment, net$11M$12.3M$12.4M$11M$9.08M
Goodwill and intangible assets$175.5M$187M$160.2M$26.2M$17.5M
Long-term investments$0.00$0.00$0.00$0.00$11.1M
Total non-current assets$187.7M$199.3M$172.7M$39.1M$37.7M
Total assets$399.5M$389M$311.8M$157.4M$98.3M
Accounts payable$35.4M$38.8M$21.4M$6.44M$5.17M
Short-term debt$890K$500K$810K$720K$280K
Deferred revenue$790K$40K$0.00$110K$20K
Total current liabilities$96.3M$91.3M$49.3M$18.6M$9.72M
Long-term debt$251.1M$228.3M$189.7M$111.5M$77.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$251.1M$228.3M$192.4M$111.5M$77.7M
Capital lease obligations$7.91M$9.29M$6.52M$8.05M$6.3M
Total liabilities$347.4M$319.7M$241.8M$130.1M$87.4M
Common stock$40K$40K$40K$30K$30K
Retained earnings-$-156.52M-$-151.38M-$-133.9M-$-109.49M-$-95.41M
Accumulated other comprehensive income (loss)$0.00$0.00-$-410K$0.00$0.00
Total equity$52.1M$69.3M$70M$27.2M$10.9M
Total investments$0.00$0.00$8.68M$5.59M$19.6M
Total debt$252M$228.8M$190.5M$112.2M$78M
Net debt$179.1M$181.6M$116.4M$16M$35.8M
Cash flow statement
20252024202320222021
Net income-$-5.14M-$-17.48M-$-24.41M-$-14.09M-$-18.01M
Depreciation and amortization$19.7M$14.5M$12.3M$3.67M$2.4M
Stock-based compensation$12.5M$17.6M$15.7M$7.97M$5.75M
Change in working capital$180K-$-44.63M-$-7.13M-$-5.57M-$-250K
Accounts receivable$5.01M-$-80.23M-$-30.34M-$-1.86M-$-1.83M
Inventory-$-2.82M$170K-$-4.33M-$-2.32M-$-260K
Accounts payable-$-4.61M$37.5M$31.8M$930K$1.73M
Net cash provided by operating activities$43.9M-$-22.2M$3.84M$1.71M$5.08M
Investments in property, plant and equipment-$-890K-$-1.59M-$-1.46M-$-2.6M-$-1.79M
Acquisitions, net-$-4.36M$0.00$0.00$0.00$9.83M
Net cash used for investing activities-$-5.46M-$-33.16M-$-152.55M-$-1.74M-$-18.69M
Common stock issued$470K$1.11M$64.5M$22.7M$70K
Common stock repurchased$0.00$0.00$0.00$0.00-$-11M
Dividends paid$0.00$0.00$0.00$0.00-$-130K
Net cash used for financing activities-$-12.72M$28.5M$126.5M$54.1M$51.5M
Net change in cash$25.7M-$-26.84M-$-22.18M$54.1M$37.9M
Cash at end of period$72.9M$47.3M$74.1M$96.3M$42.2M
Operating cash flow$43.9M-$-22.2M$3.84M$1.71M$5.08M
Capital expenditure-$-1.1M-$-38.67M-$-152.55M-$-7.77M-$-28.51M
Free cash flow$42.8M-$-60.88M-$-148.71M-$-6.07M-$-23.43M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Harrow Health, Inc.

        Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.

        CEO
        Mark L. Baum
        Employees
        373
        Beta
        0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of Harrow Health, Inc. (HROW)?

        Harrow Health, Inc. (HROW) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is HROW undervalued?

        HROW trades at a price of $30.41 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.